SEC 13F Intelligence

Duquesne Family Office LLC / RXRX

Duquesne Family Office LLC’s Recursion Pharmaceuticals In Position

Does Duquesne Family Office LLC own Recursion Pharmaceuticals In (RXRX)? Not currently — the last reported position was 906.8K shares worth $9M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$9M
Q4 2023
Shares
906.8K
% of Portfolio
+0.27%
Quarters Held
10
position exited

Position History RXRX

Reported value by quarter
Q3 ’21: $6MQ3 ’21Q4 ’21: $4MQ1 ’22: $2MQ1 ’22Q2 ’22: $2MQ3 ’22: $15MQ3 ’22Q4 ’22: $11MQ1 ’23: $9MQ1 ’23Q2 ’23: $10MQ3 ’23: $7MQ3 ’23Q4 ’23: $9Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q4 2023906.8K$9M+0.27%
Q3 2023906.8K$7M+0.25%
Q2 20231.39M$10M+0.36%
Q1 20231.39M$9M+0.40%
Q4 20221.39M$11M+0.53%
Q3 20221.39M$15M+0.84%
Q2 2022273.6K$2M+0.16%
Q1 2022273.6K$2M+0.08%
Q4 2021259.9K$4M+0.16%
Q3 2021259.9K$6M+0.19%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Duquesne Family Office LLC’s full portfolio or all institutional holders of RXRX.